Cargando…

Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study

Research Question: What is the effect of gonadotropin-releasing hormone (GnRH)-agonist treatment on serum anti-Müllerian hormone (AMH)? Design: This prospective cohort study conducted in a tertiary university hospital comprised patients (n = 52) who self-administered daily triptorelin (0.1 mg/0.1 mL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drakopoulos, Panagiotis, van de Vijver, Arne, Parra, Jose, Anckaert, Ellen, Schiettecatte, Johan, Blockeel, Christophe, Hund, Martin, Verhagen-Kamerbeek, Wilma D. J., He, Ying, Tournaye, Herman, Polyzos, Nikolaos P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399150/ https://www.ncbi.nlm.nih.gov/pubmed/30863367 http://dx.doi.org/10.3389/fendo.2019.00115

Ejemplares similares

EStradiol and PRogesterone in In vitro ferTilization (ESPRIT): a multicenter study evaluating third- versus second-generation estradiol and progesterone immunoassays
por: Polyzos, N. P., et al.
Publicado: (2020)

The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments
por: Anckaert, Ellen, et al.
Publicado: (2012)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

Type and dose of gonadotropins in poor ovarian responders: does it matter?
por: Boudry, Liese, et al.
Publicado: (2021)

The Effect of Dose Adjustments in a Subsequent Cycle of Women With Suboptimal Response Following Conventional Ovarian Stimulation
por: Drakopoulos, Panagiotis, et al.
Publicado: (2018)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Anti-Müllerian hormone concentrations in women with chronic kidney disease
por: Wiles, Kate, et al.
Publicado: (2019)

Anti-Müllerian hormone concentrations in women with chronic kidney disease
por: Wiles, Kate, et al.
Publicado: (2020)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Low Testosterone and Semen Parameters in Male Partners of Infertile Couples Undergoing IVF with a Total Sperm Count Greater than 5 Million
por: Di Guardo, Federica, et al.
Publicado: (2020)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

To delay or not frozen embryo transfer in freeze-all cycles?
por: Drakopoulos, Panagiotis, et al.
Publicado: (2020)

Poor ovarian response and the possible role of natural and modified natural cycles
por: Di Guardo, Federica, et al.
Publicado: (2022)

The Future of Luteal Phase Support in ART and the Role of Dydrogesterone
por: Drakopoulos, Panagiotis, et al.
Publicado: (2021)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Gonadotropin inhibitory hormone downregulates steroid hormone secretion and genes expressions in duck granulosa cells
por: Chen, Shijian, et al.
Publicado: (2021)

SUN-250 Effects of Anti-Mullerian Hormone on the Expression of Gonadotropin Subunits in Pituitary Gonadotroph Cell Models
por: Kanasaki, Haruhiko, et al.
Publicado: (2020)

Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept
por: Drakopoulos, Panagiotis, et al.
Publicado: (2020)

Clinical pregnancy rate for frozen embryo transfer with HRT: a randomized controlled pilot study comparing 1 week versus 2 weeks of oestradiol priming
por: Racca, Annalisa, et al.
Publicado: (2023)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Serum levels of anti-Müllerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist treatment: a retrospective cohort study
por: Hou, Yanru, et al.
Publicado: (2023)

Anti-Müllerian hormone as a marker of steroid and gonadotropin action in the testis of children and adolescents with disorders of the gonadal axis
por: Edelsztein, Nadia Y., et al.
Publicado: (2016)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone
por: Jung, Mo Kyung, et al.
Publicado: (2014)

Influence of Gonadotropin Hormone Releasing Hormone Agonists on Interhemispheric Functional Connectivity in Girls With Idiopathic Central Precocious Puberty
por: Chen, Tao, et al.
Publicado: (2020)

Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol
por: Hund, Martin, et al.
Publicado: (2014)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
por: Halim, Binarwan, et al.
Publicado: (2022)

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
por: Choi, Seungtaek, et al.
Publicado: (2011)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
por: Han, Eun Jin, et al.
Publicado: (2013)

Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells
por: Scaruffi, Paola, et al.
Publicado: (2019)

Clinical Utilities of Anti-Müllerian Hormone
por: Russell, Nicole, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kfgtjql2v5huvavh7iaegcn22d